Description: Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Statera has one of the largest platforms of toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. TLRs are a class of protein that plays a key role in the innate immune system. Statera is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. Statera has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis.
Home Page: www.staterabiopharma.com
STAB Technical Analysis
4333 Corbett Drive
Fort Collins,
CO
80525
United States
Phone:
888 613 8802
Officers
| Name | Title |
|---|---|
| Mr. Michael Kevin Handley | CEO, Pres & Chairman |
| Mr. Christopher Zosh | Exec. VP of Fin., Interim Principal Financial Officer & Interim Principal Accounting Officer |
| Dr. Robert W. Buckheit Jr., Ph.D. | Chief Technology Officer |
| Todd Headley | Exec. VP of Corp. Devel. |
| George Wagner | Exec. VP of Regulatory Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.1575 |
| Price-to-Sales TTM: | 1.6113 |
| IPO Date: | 2006-07-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 46 |